IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit

Core Viewpoint - ImmunityBio, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product, Anktiva, which is claimed to be a cancer treatment. The lawsuit highlights significant concerns about the company's marketing practices and the efficacy claims of its product [1][4][5]. Company Overview - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations of the Lawsuit - The lawsuit alleges that ImmunityBio made false claims about Anktiva, including that it would allow all NMIBC patients to be cancer-free long-term, which has not been proven [4]. - It is claimed that the assertion that Anktiva is a cancer vaccine is false, and the Executive Chairman overstated the product's capabilities [4]. - A warning letter from the U.S. FDA indicated that promotional materials misbranded Anktiva, leading to a 21% drop in stock price following the news [5]. Legal Process - Investors who purchased ImmunityBio securities during the specified class period (January 19, 2026, to March 24, 2026) can seek to be appointed as lead plaintiff in the class action lawsuit [1][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone, and $8.4 billion over the past five years [7].